$TNGX vopimetostat daraxonrasib ORR PDAC

Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner! doi.org/10.1158/0008-5472.CA…

Thanks a lot for attending the Best of JCO Global Oncology Session and making it a grand success. @KVanLoonMD @JCOGO_ASCO @ASCO

2/The pick: a phase 3 LBA from Menon's group at Tata Memorial, Mumbai — low-dose pembrolizumab chemo in advanced NSCLC. Why follow a result we haven't seen? Because of what this exact group has already proven in print.

Proud to share ph III RCT on low-dose abiraterone (250 mg w/food) vs std-dose abi in CRPC. Despite markedly lower drug exposure, low-dose abi had comparable efficacy, safety & QoL: supporting affordable and practical treatment ascopubs.org/doi/10.1200/GO-… #ProstateCancer @OncoAlert

With 75% of cancer deaths in low-income countries due to high costs, JCO Global Oncology prioritizes affordable research to close the equity gap. Join #ASCO26 to discuss improving care: Saturday, May 30 4:45 – 6 PM (CT) Room S403 View the full schedule: bit.ly/4wLqqJo

After a valiant battle with cancer, we lost my former staffer Asal Sayas. She had many friends and admirers, including me. While battling her own cancer, she worked on President Biden’s Cancer Moonshot to expand access to clinical trials. My heart is with her loved ones.

Stanford Medicine researchers have found a critical link between bacteria living in the gut and aging-related cognitive decline. med.stanford.edu/news/all-ne…

With the big boss from @pmcancercentre 🙌🏽 Thank you once again for the honour 🙏🏽

Do participate in this Global survey initiated by Dr Karan Sood @QuantumOnc and colleagues Asthenia isn't rare It is ignored. Let's understand it better @MedwatchKate @Larvol @OncBrothers @allisonoconn @PTarantinoMD @dr_yakupergun Link below 🙂👇 docs.google.com/forms/d/e/1F… .

📊Early insights on Asthenia Survey: 89.4% see it often 68.2% aren’t satisfied with the current treatment "Asthenia is common." Our systems to address it? Not enough. ⏱4 minutes to contribute 🔁Please reshare to expand reach 🔗 forms.gle/R6oz4zWioxrjAS8i6

2026 is the year capital flows into biotech. 2012 - CRISPR discovered, nobody knows what to do with it 2018 - Gene therapy costs $2M per treatment, completely unscalable 2020 - mRNA works but gets written off as a COVID fluke 2023 - AI eats software, biotech still stuck in 20-year timelines 2024 - Autonomous labs emerge, longevity gets institutional backing 2025 - FDA shifts, manufacturing costs drop 40%, DeSci bypasses gatekeepers 2026 - AI running 36K experiments autonomously, gene therapy costs dropped 40%, FDA fast-tracking, €2.5M crowdfunded in 72 hours, and biology just hit software velocity bio/acc.

🔥🚨BREAKING: A petri dish filled with human brain cells just learned to how to play DOOM Scientists at Cortical Labs have successfully trained a cluster of approximately 200,000 living human neurons, grown on a microelectrode array chip, to play the classic 3D video game DOOM.

Please follow the link and help gather data on asthenia in cancer care. It is helpful to have better insight in the subject.

@PTarantinoMD @JCOGO_ASCO @purvish1 @ajumathew_ @maryam_lustberg @TataMemorialCtr @TataMemorial @nihardesai89 @NazliDizman @SewantiLimaye @BalazsHalmosMD @EHA_Hematology @Amolpatel_dr @oncology_bg

Tomás Vega invented a MouthPad, a groundbreaking device that enables people with paralysis to control digital devices using tongue, mouth, and head gestures.

A brief history of p53-targeting cancer therapies 2003 — Gendicine, a p53 gene therapy, approved in China (but not elsewhere) 2012 — The first small molecule MDM2 inhibitor (RG7112, which works by preventing degradation of p53) enters trials, but did not progress to approval 2013 — Second-generation MDM2 inhibitor (Idasanutlin) reached phase 3, but failed and was dropped 2017 — A dual MDM2/MDMX inhibitor, ALRN-6924, enters trials; it has not since been approved 2020–2021 — A mutant p53 reactivator, Eprenetapopt, fails in phase 3 2023 — An MDM2 inhibitor, Milademetan, fails in phase 3 2024 — Promising phase 1 data for an MDM2 degrader 2026 — Rezatapopt phase 1 data: very promising early data, specific for the p53 Y220C mutation (present in 1% of all solid tumours)

Our cancer support session on Managing the Side Effects of Treatment During Cancer Treatment brought together expert medical guidance and meaningful patient conversations. With insights from Dr. Karan Sood, Medical Oncologist, the discussion focused on understanding common treatment-related side effects, practical management strategies, and improving day-to-day quality of life during cancer care. The session featured patient perspective from Ms. Urvashi Prasad and was hosted by Mr. Vivek Sharma, Founder of Uhapo, reinforcing a shared commitment to patient support and empowerment. Thank you to everyone who joined and contributed to making this session informative and impactful. Watch on YouTube - youtu.be/Bk2g1nfSDhU?si=hCbX… #CancerSupport #OncologyCare #PatientWellbeing #Uhapo #CancerCommunity